Fall 9-1-2001

PHAR 552.01: Therapeutics III

Michael P. Rivey

*University of Montana, Missoula*

Let us know how access to this document benefits you.

Follow this and additional works at: [https://scholarworks.umt.edu/syllabi](https://scholarworks.umt.edu/syllabi)

**Recommended Citation**

Rivey, Michael P., "PHAR 552.01: Therapeutics III" (2001). Syllabi. 6209.
[https://scholarworks.umt.edu/syllabi/6209](https://scholarworks.umt.edu/syllabi/6209)

This Syllabus is brought to you for free and open access by the Course Syllabi at ScholarWorks at University of Montana. It has been accepted for inclusion in Syllabi by an authorized administrator of ScholarWorks at University of Montana. For more information, please contact [scholarworks@mso.umt.edu](mailto:scholarworks@mso.umt.edu).
Lectures: M-W-Th 1010-1100 Rm 114, Skaggs Building
F only 1010-1100 Rm 336, Skaggs Building
(note: joint lectures with Pharm.D class in SB114 or 117)
(note: 595 lectures on Weds 0910-1000 in SB 336)

Course Coordinator: Michael Rivey ===> M. Rivey
Instructors: Douglas Allington Office: 243-6796
Rose Macklin Community Hosp: 728-4100 ext. 7605
Cathy Bartels
Sarah Miller Pager: 329-6122
Gayle Cochran Home: 251-3369
Donna Beall Larry Dent
Lee Ann Bradley Vince Colucci
William Docktor Tim Stratton

Material and Resources
Required Texts: DiPiro *Pharmacotherapy, 4th edition*
APhA: *Handbook of Nonprescription Drugs*
Medical Letter on Drugs & Therapeutics
Goodman & Gilman's *Pharmacological Basis of Therapeutics*
Boh *Pharmacy Practice Manual*
A medical dictionary

Optional Texts: Murphy: *Clinical Pharmacokinetics pocket reference*
Evans: *Applied Pharmacokinetics*
Young, Koda-Kimble: *Applied Therapeutics*
Hansten & Horn: *Drug Interactions*
Pagana & Pagana: *Diagnostic & Lab Test Ref.*, or other lab. text

Goals of the Course

To promote the students' understanding of common disease states with particular emphasis on the facets of diseases that are amenable to drug therapy.

To familiarize the student with the proper use of drugs in a clinical setting.

To develop the students' awareness of factors that should be considered prior to selection of a drug and the appropriate parameters that should be monitored for therapeutic as well as undesired effects.

To encourage the students' ability to problem-solve in the clinical setting.
Performance Objectives
Upon completion of this course, each student shall be able to:

Relate the pathophysiology of a disease to the known or purported action of a drug.

Evaluate the seriousness of a disorder based on the signs and symptoms related to a diagnosed problem, and:
--determine the necessity of drug therapy,
--when applicable, choose the proper drug and/or drug product for the situation.

Determine the place of non-pharmacologic and natural therapies, when applicable.

Tailor the drug therapy of an individual based on patient characteristics and known pharmacokinetics principles.

Identify potential drug-drug interactions.

Monitor the appropriate parameters of a disease to determine if the patient is responding positively to therapy.

Monitor for adverse drug reactions and exacerbations of underlying patient problems resulting from drug therapy.

Student Responsibilities and Obligations

* To attend and participate in lecture sessions.

* To do assigned readings from the texts.

* To attend Integrated Studies conferences, prepare each case in advance, prepare to present a patient case, and participate in the discussion of all patient presentations.

* To perform satisfactorily on course quizzes and lecture examinations.
GRADING IN COURSE: Phar 552-BS Therapeutics

3 midterm exams: 100 points each  300 points
Final exam (comprehensive, multiple choice)  130 points
(100 pts comprehensive, 30 pts over last 6 lectures)
Topic quizzes: 8 quizzes graded on 10 pts each Bonus pts > 75%
TOTAL POINTS FOR COURSE  430 POINTS

Class quizzes: The purposes of the quizzes are to promote reading of the text before a topic. Quizzes will occur before topic lectures and will test understanding of basic concepts in the reading assignments. A quiz will consist of 5 multiple choice or true/false questions, each worth 2 points. QUIZ on syllabus indicates a quiz will be given for the overall topic at start of the given lecture and will concern only assigned reading for that day. Lowest 2 quiz grades will be thrown out; no make-ups will be allowed for quiz. Scoring: Quiz performance can only benefit student; bonus points for the course will be awarded for all points over 75% (i.e. 60 pts) of the potential total 80 pts on the quizzes (10 total quizzes – 2 throw-outs = 8x10 pts)

NOTE: Reading assignments are from DiPiro (4th edition) & APhA books

Integrated Studies Conferences: you will be assigned to a conference based on period you registered for; instructors are not necessarily the ones under which you registered. Attendance/make-up is required for all topics/cases; you may attend a different conference in order to complete the assignment, with instructor permission. The “make-up” requirement for a conference will be at the discretion of the instructor, dependent on the topic.

Exams:
3 midterm exams: Tests will be in "traditional" case report fashion with short answers required. Tests will be given during a “common” time period. B.S. and Pharm.D. classes will take tests simultaneously.

Final exam: 65 multiple choice questions worth 2 pts each. Effort will be made to design questions in the style similar to the NAPLEX exam.

Class civility: Your student colleagues have strongly indicated to us that they wish to spend their valuable time in class listening to therapeutics topics. They do not appreciate any “side” conversations while the instructor is lecturing. They do appreciate students raising questions about important lecture aspects for further discussion or clarification.

Out of respect for your classmates, we will not tolerate excessive and disruptive talking during lecture. The instructor may first ask you to be silent; you may be asked to leave class if you persist in disruptive talking. The instructor will be the judge of “what” constitutes disruption. Please note that we encourage questions and relevant discussion.
<table>
<thead>
<tr>
<th>Week</th>
<th>Date</th>
<th>Topic</th>
<th>Instructor</th>
<th>Reading</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sept</td>
<td>5W</td>
<td>Introduction/ Liver disease (9AM SB336)</td>
<td>MPR (595)</td>
<td>35, 38</td>
</tr>
<tr>
<td></td>
<td>5W</td>
<td>Liver disease</td>
<td>MPR</td>
<td></td>
</tr>
<tr>
<td></td>
<td>6Th</td>
<td>Liver disease</td>
<td>MPR</td>
<td></td>
</tr>
<tr>
<td></td>
<td>7F</td>
<td>Renal disease/ (10AM in SB 114)/ QUIZ DRA</td>
<td></td>
<td>40</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>10M</td>
<td>Renal disease</td>
<td>DRA</td>
<td>42</td>
</tr>
<tr>
<td></td>
<td>12W</td>
<td>Hypertension</td>
<td>LAD (595)</td>
<td>JNC-6 download</td>
</tr>
<tr>
<td></td>
<td>12W</td>
<td>HTN</td>
<td>LAD</td>
<td>10</td>
</tr>
<tr>
<td></td>
<td>13Th</td>
<td>HTN</td>
<td>LAD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>14F</td>
<td>Pain Management (10 AM SB114)</td>
<td>LAB</td>
<td>56, OTC 18</td>
</tr>
<tr>
<td></td>
<td>17M</td>
<td>Pain mgmt (11AM SB117)</td>
<td>LAB</td>
<td></td>
</tr>
<tr>
<td></td>
<td>19W</td>
<td>Drug Literature Evaluation</td>
<td>CLB (595)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>19W</td>
<td>Headache (11AM SB 117)/ QUIZ</td>
<td>DB</td>
<td>57</td>
</tr>
<tr>
<td></td>
<td>20Th</td>
<td>Congestive Heart Failure</td>
<td>VJC</td>
<td>11</td>
</tr>
<tr>
<td></td>
<td>21F</td>
<td>Headache (10AM SB 114)</td>
<td>DB</td>
<td>OTC 25</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>24M</td>
<td>CHF</td>
<td>VJC</td>
<td></td>
</tr>
<tr>
<td></td>
<td>25T</td>
<td>Career Fair</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>26W</td>
<td>Drug Literature Evaluation</td>
<td>CLB (595)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>26W</td>
<td>CHF</td>
<td>VJC</td>
<td></td>
</tr>
<tr>
<td></td>
<td>27Th</td>
<td>Digoxin kinetics</td>
<td>VJC</td>
<td></td>
</tr>
<tr>
<td></td>
<td>28F</td>
<td>Coronary Artery Disease</td>
<td>VJC</td>
<td>12</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oct</td>
<td>1M</td>
<td>CAD</td>
<td>VJC</td>
<td></td>
</tr>
<tr>
<td></td>
<td>3W</td>
<td>Drug Literature Evaluation</td>
<td>CLB (595)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>3W</td>
<td>Arthritis (11AM SB 117)/ QUIZ</td>
<td>MPR</td>
<td>84</td>
</tr>
<tr>
<td></td>
<td>4Th</td>
<td>Arthritis</td>
<td>MPR</td>
<td>83</td>
</tr>
<tr>
<td></td>
<td>5F</td>
<td>Arthritis (note!! 11AM SB 117)</td>
<td>MPR</td>
<td>OTC pp 71-2, OTC5</td>
</tr>
<tr>
<td></td>
<td>5F</td>
<td>Test 1 at 1-3 PM in SB 114; through Dig PK</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>8M</td>
<td>Gout (11AM SB 117)</td>
<td>MPR</td>
<td>85</td>
</tr>
<tr>
<td></td>
<td>10W</td>
<td>Drug Literature Evaluation</td>
<td>CLB (595)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>10W</td>
<td>Hyperlipidemia</td>
<td>LAD</td>
<td>ATP III download</td>
</tr>
<tr>
<td></td>
<td>11Th</td>
<td>Hyperlipidemia</td>
<td>LAD</td>
<td>19</td>
</tr>
<tr>
<td></td>
<td>12F</td>
<td>Contraception (10AM SB114)/ QUIZ</td>
<td>DB</td>
<td>OTC 8</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>15M</td>
<td>Contraception</td>
<td>DB</td>
<td>76</td>
</tr>
<tr>
<td></td>
<td>17W</td>
<td>Contraception</td>
<td>DB (595)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>17W</td>
<td>Dysrhythmias</td>
<td>VJC</td>
<td>14</td>
</tr>
<tr>
<td></td>
<td>18Th</td>
<td>off day- no class</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>19F</td>
<td>off; ASP-MRM meeting in Seattle</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Oct 22M Menopause (11 AM SB 117)/ QUIZ GAC 78
24W Drug Literature Evaluation CLB (595) 24W Menopause (11 AM SB 117) GAC 61
25Th Dementia GAC 26F Osteoporosis (10 AM SB 114) GAC 82, OTC 419-20
29M Osteoporosis (11 AM SB 117) GAC
31W Drug Literature Evaluation CLB (595) 31W Dementia GAC 61

Nov 1Th Theophylline kinetics DRA 2F OAD (10 AM SB 114) DRA 25, OTC 10
2F Test 2 at 1-3 PM n SB 114; through osteoporosis
5M Oncology overview CLB DiPiro pp.2013-41 5
7W Oncology overview CLB (595) 7W Thromboembolic Disease (11 AM SB 117) MPR 17
8Th TED MPR 9F Stroke/ (10 AM SB 114)/ QUIZ MPR 18

12M VETERANS DAY HOLIDAY
14W Nausea & vomiting LAB (595) 33, OTC 5
15W Seizure dx/ QUIZ DRA 52
15Th Seizure disorders DRA 16F Anticonvulsant kinetics DRA
19M Fluid & electrolytes SJM DiPiro pp 890-902
21W OFF; TRAVEL DAY
22Th THANKSGIVING HOLIDAY
23F “ “

26M F&E SJM pp 902-16
28W Biostatistics overview TPS (595) 28W Nutrition SJM
29Th Thyroid disorders MPR 71
30F Diabetes mellitus/ QUIZ LRM 70

Dec 3M DM LRM
5W Biostatistics overview TPS (595) 5W DM tests LRM OTC 39
6Th Anxiety/sleep disorders WJD 67, 69, OTC 24
7F Test 3 at 1-3 PM in SB 114; through nutrition
552-Ther III & Phar 595, continued

<table>
<thead>
<tr>
<th>Day</th>
<th>Topic</th>
<th>Instructor</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>10M</td>
<td>Attention deficit disorder</td>
<td>WJD</td>
<td>DiPiro pp. 1046-49</td>
</tr>
<tr>
<td>12W</td>
<td>Biostatistics overview</td>
<td>TPS (595)</td>
<td></td>
</tr>
<tr>
<td>12W</td>
<td>CLASS EVALUATION</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13Th</td>
<td>Depression/ QUIZ</td>
<td>WJD</td>
<td>65</td>
</tr>
<tr>
<td>14F</td>
<td>Depression</td>
<td>WJD</td>
<td></td>
</tr>
</tbody>
</table>

Phar 552-BS Final: test 4, 130 pts comprehensive multiple choice NAPLEX/PSAP format
Phar 595 Final: see below; biostatistics questions added to Final

NOTE: class will meet at 10AM or 11AM (if meeting together with Pharm.D. class) on days throughout the semester

Pharmacy 595: supplemental course

Phar 595: Course is 1-hour Wednesday session to supplement Ther-III and cover other topics not in B.S. curriculum in an overview fashion. It is graded course

Schedule: merged to above syllabus (weekly on Weds at 0910-1100 in SB 336)

Instructors: various Therapeutics instructors
            Cathy Bartels
            Tim Stratton

Grading in Phar 595:

6/14 of course grade: project in Drug Literature Evaluation
3/14 of course grade: biostatistics questions on Final Exam (add-on questions)
5/14 of course grade: grade obtained in Ther. Phar 552 course
Integrated Studies Phar 574

I. Conference topics

Tuesday 0910-1100 SB335 Rivey
Tuesday 0910-1100 SB337 Colucci

week of:

September  
3M no conference
10M Liver disease case
17M Hypertension case
24M Headache/pain management

October  
1M Digoxin kinetics
8M J-club for ½ of class; service learning work session
15M OTC cases
23M Contraception
29M service learning update: J-club for other ½ of class

November  
5M SEMINARS
12M OAD case
19M off week- holiday week
26M TED case

December  
3M OTC cases
10M Evaluation/ Diabetes case

Seminar: A required activity in the course, graded on a pass/no-pass basis. Student must repeat a no-pass seminar to successfully pass course.